Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)GlobeNewsWire • 10/24/24
Novartis Gets CHMP Recommendation for Kisqali in Broader PopulationZacks Investment Research • 10/21/24
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancerPRNewsWire • 10/18/24
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great MoveThe Motley Fool • 10/17/24
Novartis: Value Continues To Build With Double-Digit Percentage Growth ProductsSeeking Alpha • 09/30/24
Novartis: Best Performing Big Pharma Of Past 6 Months Still Looks A Solid Long-Term BetSeeking Alpha • 09/26/24
Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AIBusiness Wire • 09/24/24
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancerGlobeNewsWire • 09/17/24
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancerGlobeNewsWire • 09/16/24
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage StudyZacks Investment Research • 08/29/24
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery InnovationBusiness Wire • 08/28/24